Barclays raised the firm’s price target on Kymera Therapeutics (KYMR) to $119 from $70 and keeps an Overweight rating on the shares. The firm updated the company’s model following the Phase 1b BroADen update. The data “significantly de-risks” KT-621’s potential in T helper 2 cells driven disease, the analyst tells investors in a research note. Barclays sees share upside if KT-621 can achieve “Dupi-like sales.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics’ KT-621: Promising Market Potential and Competitive Positioning in Atopic Dermatitis Treatment
- Closing Bell Movers: Toll Brothers slips 4% after Q4 earnings miss
- Kymera Therapeutics price target raised to $118 from $70 at Leerink
- Kymera Therapeutics offers to sell $500M in common stock
- Kymera Therapeutics price target raised to $138 from $75 at BTIG